Evidence map›Paper›PMID 41334707›Full record

ArticleProteomics2026

Metabolic Profiling of the EmDia Cohort by LC-MS Reveals Empagliflozin-Intake Associated Regulation of 1,5-anhydroglucitol and Urate.

Fabian Schmitt, Vincent Ten Cate, Zlatka Fischer, Mathias Hagen, Barbara A Steigenberger, Stefan Tenzer, Philipp S Wild, Thierry Schmidlin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fabian SchmittInstitute of Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Vincent Ten CatePreventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Zlatka FischerPreventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Mathias HagenInstitute of Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Barbara A SteigenbergerMass Spectrometry Core Facility, Max Planck Institute of Biochemistry, Martinsried, Germany.
Stefan TenzerInstitute of Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Philipp S WildPreventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Thierry SchmidlinInstitute of Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.

Funding

Federal Ministry of Research, Technology and Space 01EO1503Federal Ministry of Research, Technology and Space 031L0218Federal Ministry of Research, Technology and Space 161L0217A
6 · The paper itself

Abstract

The EmDia trial, designed to study the effects of the sodium glucose cotransporter-2 (SGLT2) inhibitor empagliflozin on cardiovascular comorbidities in type 2 diabetes mellitus (T2DM) patients, has been investigated for short-term metabolic alterations by a limited set of clinical assays. To expand on this data, we report on the development of a liquid chromatography-mass spectrometry (LC-MS)-based metabolomics approach employing an optimized metabolite separation by pentafluorophenyl chromatography. High-confidence metabolite annotation based on reference standards allows for fast and robust metabolic characterization of large plasma cohorts due to scalability. Applied to EmDia, we show the high predictive power of our methodology for several clinical parameters, including a near-perfect prediction of fasting blood glucose (R

Indexed as

Benzhydryl CompoundsDeoxyglucoseDiabetes Mellitus, Type 2GlucosidesMetabolomeMetabolomicsSodium-Glucose Transporter 2 InhibitorsAgedBiomarkersBlood GlucoseChromatography, LiquidCohort StudiesFemaleHumansLiquid Chromatography-Mass SpectrometryMale1,5-anhydroglucitolBenzhydryl CompoundsBiomarkersBlood GlucoseDeoxyglucoseempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsdata‐independent acquisitionhuman plasmametabolomicsSGLT2 inhibitortype 2 diabetes mellitus

Identifiers

PMID41334707
PMCPMC12809005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.